2-[[3-(4-chlorophenoxy)phenyl]methyl]-1-methyl-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[[3-(4-chlorophenoxy)phenyl]methyl]-1-methyl-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazine
• 化学式: C₂₁H₂₅ClN₂O
• 分子量: 356.9
• InChiKey: LANXFHNBSBOPCN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  15.7
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• N-myristoyltransferase inhibitor compositions and methods of use
  申请人：——

  公开号：US20040014764A1

  公开（公告）日：2004-01-22

  The invention is a pharmaceutical composition mainly for the treatment of a hyperproliferative disease, such as cancer, atherosclerosis, restenosis or psoriasis, or viral infection. The active ingredient of the composition is a compound that inhibits the activity of human N-myristoyltransferase (NMT). The NMT inhibitors are small molecule non-lipid compounds containing a cyclohexyl-octahydro-pyrrolo[1,2-a]pyrazine (COPP) or methyl-octahydro-pyrrolo[1,2-a]pyrazine (MOPP) group.